Bain Capital Life Sciences Investors, LLC Long-Term Concentrated

CIK: 0001703031 · Show all filings

Period: Q3 2018 (← Previous) (Next →)

Filing Date: Nov 14, 2018

Total Value ($000): $440,629 (100.0% shares, 0.0% debt)

Holdings (6)

— DICERNA PHARMACEUTICALS INC 30.9%

Value ($000) $136,275 Shares 8,930,237 Est. Cost $9.03 Unrealized —

— SOLID BIOSCIENCES INC 21.3%

Value ($000) $93,862 Shares 1,989,444 Est. Cost $7.50 Unrealized —

— APTINYX INC 14.6%

Value ($000) $64,439 Shares 2,225,092 Est. Cost $24.17 Unrealized —

IFRX INFLARX NV 13.7%

Value ($000) $60,571 Shares 1,764,888 Est. Cost $17.97 Unrealized +79.5%

REPL REPLIMUNE GROUP INC 10.4%

Value ($000) $45,707 Shares 2,838,968 Est. Cost $17.53 Unrealized 0.0%

— MARINUS PHARMACEUTICALS INC 9.0%

Value ($000) $39,775 Shares 3,977,453 Est. Cost $8.16 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	DICERNA PHARMACEUTICALS INC	8,930,237	$136,275	30.9%	$9.03	—	COM	253031108
—	SOLID BIOSCIENCES INC	1,989,444	$93,862	21.3%	$7.50	—	COM	83422E105
—	APTINYX INC	2,225,092	$64,439	14.6%	$24.17	—	COM	03836N103
IFRX	INFLARX NV	1,764,888	$60,571	13.7%	$17.97	+79.5%	COM	N44821101
REPL	REPLIMUNE GROUP INC	2,838,968	$45,707	10.4%	$17.53	0.0%	COM	76029N106
—	MARINUS PHARMACEUTICALS INC	3,977,453	$39,775	9.0%	$8.16	—	COM	56854Q101